Courtesy www.franchiseindia.com
New Delhi: Drug Controller General of India (DCGI) on Friday approved restricted emergency use of Zydus Cadila’s ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infections in adults.
The approval follows promising results from a late-stage study of the drug, and comes in the middle of a massive wave of COVID-19 cases in India, which has overwhelmed its health system and left many hospitals short of critical oxygen supplies.
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications. Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup,” the company said in a filing.
Bhubaneswar: Twelve members of Village Water and Sanitation Committees (VWSC) from nine districts of Odisha…
Hyderabad: Bollywood actress Janhvi Kapoor, who is rumoured to be dating Shikhar Pahariya, had once…
Bhubaneswar: In a remarkable stride toward strengthening industrial ecosystem, the Odisha government on Wednesday approved…
Bengaluru: Playing away from home, Odisha FC turned the game on its head to snatch a…
Hyderabad: Two weeks after its Telugu release, the Hindi version of Balakrishna-Urvashi Rautela starrer ‘Daaku…
Bhubaneswar: The State Cabinet on Wednesday cleared the path for recruitment of 5,000 doctors by…
This website uses cookies.
